Csenge Advisory Group Purchases Shares of 1,152 Axon Enterprise, Inc $AXON

Csenge Advisory Group acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,152 shares of the biotechnology company’s stock, valued at approximately $646,000.

A number of other institutional investors also recently bought and sold shares of AXON. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after purchasing an additional 53,060 shares during the period. BlackRock Inc. lifted its holdings in shares of Axon Enterprise by 4.3% during the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after purchasing an additional 345,365 shares during the period. Geode Capital Management LLC boosted its position in Axon Enterprise by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after buying an additional 35,544 shares during the last quarter. Sands Capital Management LLC boosted its position in Axon Enterprise by 11.6% in the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after buying an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after buying an additional 1,179,038 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Trading Up 4.2%

Shares of Axon Enterprise stock opened at $645.72 on Thursday. The firm has a 50-day simple moving average of $536.03 and a two-hundred day simple moving average of $474.89. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $794.29. The company has a market cap of $52.46 billion, a P/E ratio of 267.93, a price-to-earnings-growth ratio of 10.06 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. During the same period last year, the firm earned $2.12 EPS. The company’s quarterly revenue was up 35.3% on a year-over-year basis. As a group, equities analysts predict that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on AXON. Needham & Company LLC reissued a “buy” rating on shares of Axon Enterprise in a research report on Thursday, August 6th. Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 10th. Piper Sandler raised their target price on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Barclays raised their target price on shares of Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average price target of $730.92.

Insider Activity at Axon Enterprise

In other news, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total transaction of $800,000.00. Following the completion of the transaction, the insider directly owned 52,813 shares of the company’s stock, valued at $21,125,200. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider owned 34,024 shares in the company, valued at $16,501,640. This trade represents a 4.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 68,989 shares of company stock valued at $36,016,932 in the last ninety days. 4.20% of the stock is currently owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.